Background: Cyclosporine (CsA) is frequently responsible for hypertension in bone marrow transplant children. Calcium channel blockers (CCBs) are considered to be the best treatment for CsA-induced hypertension, but they may alter the exposure and the effect of CsA by inhibiting the CYP3A4 pathway of CsA metabolism or P-gp. However, the inhibitory effect on CYP3A4 may vary among CCBs. Methods: This study aimed to quantify the pharmacokinetic drug-drug interaction between CsA and nicardipine, amlodipine, and lacidipine. In all, 51 children who received CsA and CCB concomitantly were included. Results: Dose-normalized CsA trough blood concentrations significantly increased in patients treated with nicardipine and amlodipine, whereas they remained stable in patients treated with lacidipine. Conclusions: Because lacidipine appears to have no effect on CsA exposure, it may be the best option among CCBs for treating high blood pressure caused by CsA in children.
RobertNWongGWWrightJM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;(20):1-50 doi:10.1002/14651858.CD007893.
2.
HoornEJWalshSBMcCormickJAZietseRUnwinRJEllisonDH. Pathogenesis of calcineurin inhibitor–induced hypertension. J Nephrol. 2012;25:269-275 doi:10.5301/jn.5000174.
3.
RodicioJL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol. 2000;35:S7-S11.
4.
LuftFC. How calcineurin inhibitors cause hypertension. Nephrol Dial Transplant. 2012;27:473-475. doi:10.1093/ndt/gfr679.
5.
PfeilschifterJRüeggUT. Cyclosporin A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells. Biochem J. 1987;248:883-887.
6.
van der SchaafMRHenéRJFloorMBlankestijnPJKoomansHA. Hypertension after renal transplantation: calcium channel or converting enzyme blockade?Hypertension. 1995;25:77-81.
7.
KhattakSRoganJWSaundersEFTheisJGArbusGSKorenG. Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr. 1998;37:31-35.
8.
RoganJWLyszkiewiczDABloweyDKhattakSArbusGSKorenG. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol. 2000;14:1083-1087.
9.
FlynnJT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol. 2005;20:631-635.
10.
AndersenJGroshongTTobiasJD. Preliminary experience with amlodipine in the pediatric population. Am J Ther. 2006;13:198-204.
11.
GuengerichFPBrianWRIwasakiMSariMABaarnhielmCBerntssonP. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991;34:1338-1344.
12.
KatohMNakajimaMShimadaNYamazakiHYokoiT. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55:843-852.
13.
XiaZWangMZouSChenR. Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes. Eur J Drug Metab Pharmacokinet. 2012;37:211-216. doi:10.1007/s13318-011-0076-3.
14.
HebertMF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997;27:201-214.
15.
HuetEMorandKBlanchetBAstierAHulinA. Evaluation of the new heterogeneous ACMIA immunoassay for the determination of whole-blood cyclosporine concentrations in bone marrow, kidney, heart, and liver transplant recipients. Transplant Proc. 2004;36:1317-1320.
16.
BleyzacN. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam Clin Pharmacol. 2008;22:605-608. doi:10.1111/j.1472-8206.2008.00652.x.
17.
MartinPBleyzacNSouilletG. Relationship between cyclosporine trough blood concentrations and severity of acute graft-versus-host-disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 2003;32:777-784.
18.
MartinPBleyzacNSouilletG. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Trans-plant. 2003;32:881-887.
19.
WillemzeAJPressRRLankesterACEgelerRMden HartighJVossenJM. CsA exposure is associated with acute GVHD and relapse in children after SCT. Bone Marrow Transplant. 2010;45:1056-1061. doi:10.1038/bmt.2009.299.
20.
GérardCBleyzacNGirardPFreyerGBertrandYTodM. Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model. Pharm Res. 2011;28:531-539. doi:10.1007/s11095-010-0299-z.
21.
OzbayAKaramperisNJørgensenKA. A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Curr Clin Pharmacol. 2007;2:244-248.
22.
SalemFRostami-HodjeganAJohnsonTN. Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol. 2013;53:559-566.
23.
SalemFJohnsonTNBarterZELeederJSRostami-HodjeganA. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Phar-macol. 2013;53:857-865. doi:10.1002/jcph.100.
24.
ToupanceOLavaudSCanivetEBernaudCHottonJMChanardJ. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994;24:297-300.
25.
PfammatterJPClericetti-AffolterCTruttmannACBuschKLaux-EndRBianchettiMG. Amlodipine once-daily in systemic hypertension. Eur J Pediatr. 1998;157:618-621.
26.
von VigierROFransciniLMBiandaND. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens. 2001;15:387-391.
PesaventoTEJonesPAJulianBACurtisJJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients. J Am Soc Nephrol. 1996;7:831-835.
29.
CaiJHuangZYangG. Comparing antihypertensive effect and plasma cyclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy. Am J Cardiovasc Drugs. 2011;11:401-409. doi:10.2165/11593800-000000000-00000.
30.
ToddPGariochJJRademakerMThomsonJ. Nicardipine interacts with cyclosporin. Br J Dermatol. 1989;121:820.
31.
BagnisCDerayG. Calcium inhibitors in the management of hypertensive patients on cyclosporine. Arch Mal Coeur Vaiss. 1998;91:411-414.
32.
GuanDWangRLuJWangMXuC. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc. 1996;28:1311-1312.
33.
KatohMNakajimaMYamasakiHYokoiT. Inhibitory potencies of 1,4 dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000;10:1189-1197.
KuypersDRNeumayerHHFritscheL. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation. 2004;78:1204-1211.
36.
GertzMCartwrightCMHobbsMJ. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Res. 2013;30:761-780.
37.
MadsenJKJensenJDJensenLWPedersenEB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol. 1996;50:203-208.
38.
GertzMHoustonJBGaletinA. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos. 2011;39:1633-1642.
39.
DorababuMNishimuraAPrabhaT. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother. 2009;63:697-702.
